Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on March 4, 2025
Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis
GlobeNewswire
·
March 4, 2025
Ness-Ziona, Israel, March 04, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, is pleased to invite investors to a live investor webinar on March 5, 2025, at …
Build With Robots Rebrands as Breezy Med Following Strategic Investment and Healthcare Expansion
GlobeNewswire
·
March 4, 2025
Albuquerque, NM, March 04, 2025 (GLOBE NEWSWIRE) -- Build With Robots, a leader in automated disinfection solutions, is proud to announce its rebranding as Breezy Med. This transformation reflects the company’s expanded focus on healthcare and its mission …
IO Biotech Reports 2024 Business Highlights
GlobeNewswire
·
March 4, 2025
Preparations for submission of a Biologics License Application (BLA) for Cylembio® (imsapepimut and etimupepimut, adjuvanted) to FDA by year end 2025 remain on track. The trial completed enrollment in December 2023 ahead of plan with 407 patients. The …
Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
GlobeNewswire
·
March 4, 2025
THE WOODLANDS, Texas, March 04, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its fourth quarter and full year 2024 financial results on Thursday, March 6, 2025 after the markets close. …
BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering
GlobeNewswire
·
March 4, 2025
NEW HAVEN, Conn., March 04, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced the closing …
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
March 4, 2025
CHARLESTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 11,950 …
Sanuwave Health to Uplist to the Nasdaq Global Market
GlobeNewswire
·
March 4, 2025
EDEN PRAIRIE, Minn., March 04, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the “Company” or "Sanuwave”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, announced today that its common stock has been approved for …
Teknova Reports Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
·
March 4, 2025
Full year 2024 total revenue was $37.7 million, up 3% year-over-year and in line with guidance Fourth quarter 2024 total revenue was $9.3 million, up 18% over the same quarter prior year Company provides 2025 revenue guidance of $39-42 million HOLLISTER, …
Arvinas to Participate in Upcoming Investor Conferences
GlobeNewswire
·
March 4, 2025
NEW HAVEN, Conn., March 04, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in three …
Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference
GlobeNewswire
·
March 4, 2025
IRVINE, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D., Chief Scientific Officer and President, will participate in a fireside chat at the upcoming Leerink Partners …
NeuroPace Reports Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
·
March 4, 2025
-- Record quarterly revenue of $21.5 million in Q4 2024 -- -- Full-year 2025 revenue guidance of $92 to $96 million -- -- Completed an underwritten public offering of $74.8 million, using $49.5 million of the net proceeds to repurchase 100% of KCK holdings …
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
March 4, 2025
CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly-hired employees options to purchase an …
OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
·
March 4, 2025
Record full year 2024 revenue of $204.7 million increased 38% compared to prior year, and more than doubled fourth quarter 2024 adjusted EBITDA WARSAW, Ind., March 04, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) ( …
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
GlobeNewswire
·
March 4, 2025
CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare …
Strong Proof-of-Concept Data from Phase 2 Trial of PDE10A Inhibitor (CPL’36), a Novel Once-Daily Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease
GlobeNewswire
·
March 4, 2025
Statistically significant improvement in primary endpoint (UDysRS total scale) at Week 4 and positive benefit in the key secondary endpoint (UDysRS objective subscale), beginning at Day 7 Favorable tolerability profile demonstrated in both active treatment …
BeautyHealth to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025
GlobeNewswire
·
March 4, 2025
LONG BEACH, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ:SKIN), home to flagship brand Hydrafacial™, today announced it will report fourth quarter and full year 2024 financial results after market close on Wednesday, March …
Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida
GlobeNewswire
·
March 4, 2025
SCOTTSDALE, Ariz., March 04, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)- …
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
March 4, 2025
SAN DIEGO, March 04, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to …
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
March 4, 2025
CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on March 1, 2025, it awarded …
Daxor Corporation to Host Investor Conference Call to Discuss Fiscal Year 2024 Financial Results and Provide a Corporate Update on March 6, 2025
GlobeNewswire
·
March 4, 2025
Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will host an investor conference call on Thursday, March 6, 2025, at 4:30 p.m. ET. President and …